1. bookVolume 71 (2022): Edition 4 (December 2022)
Détails du magazine
License
Format
Magazine
eISSN
2544-4646
Première parution
04 Mar 1952
Périodicité
4 fois par an
Langues
Anglais
Accès libre

Omicron SARS-CoV-2 Variants in an In Silico Genomic Comparison Study with the Original Wuhan Strain and WHO-Recognized Variants of Concern

Publié en ligne: 21 Dec 2022
Volume & Edition: Volume 71 (2022) - Edition 4 (December 2022)
Pages: 577 - 587
Reçu: 19 Sep 2022
Accepté: 12 Nov 2022
Détails du magazine
License
Format
Magazine
eISSN
2544-4646
Première parution
04 Mar 1952
Périodicité
4 fois par an
Langues
Anglais
Introduction

The COVID-19 pandemic, which started at the end of 2019, continues at the dawn of 2022, with an unprecedented vigor against humanity that was unheard of in recent times (Sofi et al. 2020). The global crisis demonstrated the loss of millions of human lives, and billions underwent a dreadful experience of economic, social, and psychological distress (Rudrapal et al. 2020). The healthcare systems across the world are exhausted and racing against time to save millions of SARS-CoV-2 -infected people. During this long pandemic, different parts of the world saw multiple waves of the disease that were driven by dominant variants originating through mutations in the original SARS-CoV-2 viral genome. Consequently, Alpha, Beta, Gamma, Kappa, Delta, Mu, IHU, and Omicron have originated as novel variants with the varying potential of virulence, transmissibility, and disease severity (Choi and Smith 2021; Karim and Karim 2021). The SARS-CoV-2, like other coronaviruses, possesses an enveloped genome of positive-sense single-stranded ~ 30 kb RNA with six open reading frames (Cao et al. 2021). The genome’s two-thirds of length comprises 265 nucleotides 5’UTR, followed by 21,290 nucleotides long ORF1ab that encode poly-protein for 16 non-structural proteins. The other one-third at the 3’ end has 229 nucleotide 3’UTR and several genes that encode surface, envelope, membrane, and nucleocapsid structural proteins such as 3,822 nucleotide-S, 228 nucleotide-E, 669 nucle- otide-M, and 908 nucleotide-N, respectively. Six accessory proteins are encoded by 828 nucleotide ORF3a, 186 nucleotide ORF6, 366 nucleotide ORF7a, 132 nucleotide ORF7b, 193 nucleotide ORF8, and 117 nucleotide ORF10 genes. It is known that the viral genome is a hotspot of mutations with one of the highest mutation rates among all organisms.

Moreover, compared to DNA viruses, RNA viruses are more prone to mutations due to the low fidelity of RNA polymerase, resulting in higher rates of erroneous miss-incorporation of bases during replication. Some of these mutations might provide the endurance to the replicating virus that grants higher potential of transmission and pathogenicity, causing the emergence of a dominant variant associated with higher rates of infection, mortality, and evasiveness to the existing natural or vaccines elicited immunity. The Delta variant of SARS-CoV-2 (B.1.617.2) which was detected in India, exhibited characteristics that outweighed the previously existing Alpha and Kappa lineages, making it a dominant variant that was responsible for the calamitous second wave in India with devastating human sufferings and loss of lives (Adiga and Nayak 2021). Experimental evidence suggests that the Delta variant as compared to wild-type Wuhan‑1, was less sensitive to neutralizing antibodies from the serum of recovered individuals (six-fold loss of efficacy), and vaccine-induced antibodies (eight-fold loss of efficacy), demonstrating a potential risk of infection due to a compromised vaccine efficacy even in the vaccinated population (Mlcochova et al. 2021).

Consequently, the Delta variant was observed to be associated with a longer period of infections, higher viral load, and higher rates of re-infections, emerging as a globally dominant variant driving 2nd, 3rd, and 4th waves of COVID-19 infections in many countries worldwide. Recently on November 25, 2021, another variant of concern named Omicron (B.1.1.529) was reported in South Africa, leaving the world apprehensive about the next course of COVID-19 disease and the efficacy of vaccines (Callaway 2021). Since then, the Omicron infection has been reported in fully vaccinated individuals, and the probability of higher transmission rates has also been suggested (Gu et al. 2021). The emergence of new variants with higher virulence downplays the containment strategies and increases the risk of greater harm to human lives. Studies characterizing the genetic diversity of such variants are therefore considered significant to tracing the course of the pandemic. In this study, we have characterized the genetic alterations in the variants of concern (VOC) including the Omicron variant which exhibits a continuous evolution of the heterogeneity in the viral genome (structural and non-structural genes) in comparison to the original Wuhan SARS-CoV-2 genome and other VOCs such as Alpha, Beta, Delta, Gamma, and Mu.

The novelty of our work can be assessed from the results wherein we have described the genetic variations in the whole genome of the Omicron SARS-CoV-2 variants as compared to other studies which focused only on the spike protein of the virus. It is also the first study wherein inter-variant genomic variations have been compared, tracing the genetic variations from the original Wuhan strain to variants of concern that emerged during different waves of COVID-19 globally.

Experimental
Materials and Methods

Our laboratory has been engaged in studies related to the genetic variations in SARS-CoV-2 over the last two years. This study is an in silico analysis of the evolutionary heterogeneity of selected variants of concern compared to the original Wuhan reference. The present study included six Omicron variants retrieved from GISAID database that were Omicron (EPI_ISL_6640916) from Botswana, Omicron (EPI_ISL_6647956) from South Africa, Omicron (EPI_ISL_6647957) from South Africa, Omicron (EPI_ISL_6647961) from South Africa, Omicron (EPI_ISL_7740798) from South Africa and Omicron (EPI_ISL_8182845) from South Africa plus five VOCs isolated from Japan and retrieved from GISAID database that were Alpha (EPI_ISL_6756515), Beta (EPI_ISL_5416540), Gamma (EPI_ISL_6228367), Delta (EPI_ISL_6832166) and Mu (EPI_ISL_4470504).

The sequences of SARS-CoV-2 of the original Wuhan variant were retrieved from NCBI COVID-19 Resource Repository (https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs) The selected variants included complete genomic sequences aligned with the first characterized isolate, the Wuhan strain from China (NC_045512.2) (Lu et al. 2020). The pairwise alignment with the local alignment search tool Nucleotide-BLAST (NCBI) was used to determine the nucleotide base changes and gene variation against Wuhan standard reference. Moreover, the NCBI Protein-BLAST was used to report the corresponding amino acid changes in the protein.

Evolutionary relationships: The Neighbor-Joining method was used to build a phylogenetic tree for understanding the evolutionary relationship of the evolving variants of SARS-CoV-2 using Molecular Evolutionary Genetics Analysis Software (MEGA 4), Philadelphia, USA (Saitou and Nei 1987). As reported in the results, the clustered taxa clad in the bootstrap test included 500 replicates, which are represented as a percentage of replicate trees shown close to the branches (Felsenstein 1985). The evolutionary distances were determined by the Maximum Composite Likelihood method (Tamura et al. 2004) showing the number of base substitutions/ site units. This analysis involved a set of SARS-CoV-2 variants of concerns, including Beta, Gamma, Delta, Mu, and Omicron, along with the original Wuhan sequence. The FASTA sequence for each of the specimen variants retrieved from the database were selected, aligned, and phylogenetic association was obtained using the tools incorporated within the software. The analysis disregarded all the enigmatic positions with a pairwise deletion option for each sequence pair. A total of 29,903 positions representing the approximate length of the whole viral genome were present in the final dataset.

Results

The multi-alignment analysis showed that Omicron variants have the lowest homology compared to the original strain; they exhibited homology ranging between 99.74 to 99.3% except for Omicron (EPI_ ISL_8182845), which showed 99.84%, while the other VOCs showed homology ranging between 99.82 to 99.85%. The genomic analysis of the VOCs of SARS-CoV-2 (Alpha, Beta, Delta, Gamma, Mu, and Omicron variants) revealed 210 nucleotide changes. Most of these changes (127/210, 60.5%) were non-synonymous mutations that occurred mainly in the S gene (52/127, 40.1%) followed by ORF1a/b (43/127, 33.9%) and the N gene (11/127, 8.9%). The remaining 10.5% (22/210) and 1.9% (4/210) of the mutations were frameshift deletions and frameshift insertions, respectively (Table I).

Distribution and type of mutations among variants of concern of SARS-CoV-2.

of mutation Type3’UTRORF10N geneORF8ORF7bORF7aORF6M geneE geneORF3S geneORFa/b15’UTRTotal
Non-coding235
Non- synonymous116134255243127
Synonymous 511112 43651
Frame shift/insertion 1 34
Frame shift/deletion 415322
Nonsense11
2 21823143774823210

The comparative analysis showed that only four mutations were common among all the VOCs; one silent mutation (C241T) on the 5’UTR region, one synonymous mutation in ORF1a/b (C3037T), one non-synonymous mutation in ORF1a/b (C14408T), which changed the amino acid (P4715L), and one non-synonymous mutation in the S gene (A23403G), which changed the amino acid (D614G).

The nucleotide changes among Omicron variants resulted in 61 amino acid changes, while the nucleotide changes in other VOCs of SARS-CoV-2 (Alpha, Beta, Delta, Gamma, and Mu) showed 11 amino acid changes (Table II, III, and IV). The present study exhibited that the majority of mutations (38/61, 62.3%) among Omicron variants occurred in the S gene, 34.2% (13/38) out of that occurred in the receptor-binding domain RBD (the RBD has involved 541–319 residues of the S1 subunit), as follows: G339D, S371L, S373P, N440K, G446S, K417N, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y. The mutations indicated with the bold font representing 69.2% (9/13) of the mutations in BDR were located in the receptor-binding motif (508aa–438aa).

The unique common mutations among Omicron variants.

Nucleotide MutationProtein mutationType of mutationGene
A2832GK856RNonsynonymousORF1a/b
3T5386GSynonymousORF1a/b
G8393AA2710TNonsynonymousORF1a/b
C10449ASynonymousORF1a/b
A11537GI3758VNonsynonymousORF1a/b
C15240TSynonymousORF1a/b
A18163GI5968VNonsynonymousORF1a/b
ΔΔ21762 21764 ΔC ΔAA67VFrameshift (deletion)S gene
Δ21767–21769 ΔCATΔ69HFrameshift (deletion)S gene
Δ21770 ΔGΔ70VFrameshift (deletion)S gene
Δ21987–21988 ΔGTG142DFrameshift (deletion)S gene
Δ21989–21991 ΔGTTΔ143VFrameshift (deletion)S gene
Δ21992–21994 ΔTATΔ144YFrameshift (deletion)S gene
Δ21995 ΔGΔ145YFrameshift (deletion)S gene
G22578AG339DNonsynonymousS gene
C23202AT547KNonsynonymousS gene
C23525TH655YNonsynonymousS gene
T23599GN679KNonsynonymousS gene
C23854AN764KNonsynonymousS gene
G23948TD796YNonsynonymousS gene
C24130AN856KNonsynonymousS gene
A24424TQ954HNonsynonymousS gene
T24469AN969KNonsynonymousS gene
C25000TSynonymousS gene
C25584TSynonymousORF3a
C26270TT9INonsynonymousE gene
A26530GD3GNonsynonymousM gene
G26709AA63TNonsynonymousM gene
C28311TP13LNonsynonymousN gene
Δ28363–28364 ΔGAFrameshift (deletion)N gene
Δ28365–28367 ΔGAAΔ31EFrameshift (deletion)N gene
Δ28368–28370 ΔCGCΔ32RFrameshift (deletion)N gene
Δ28371 ΔAΔ33SFrameshift (deletion)N gene

The unique non-common mutations among Omicron variants.

Nucleotide mutationProtein mutationType of mutationGeneComment
C24503TL981FNonsynonymousS geneNot detected in (EPI-ISL-6640916) variant
ΔΔGTTTGTCTG 11283–1129Δ3674–3676 ΔLSGFrameshift (deletion)ORF1a/bNot detected in variant (EPI_ISL_6647956)
C27807T SynonymousORF7bNot detected in (EPI_ISL_8182845) variant
T13195C synonymousORF1a/bNot detected in one (EPI_ISL_8182845) variant
Ins22194T T22195GΔ211NFrameshift (deletion)S gene
T22197G A22198CL212INonsynonymousS gene
INS22202–22203 AGINS22203–22204 CAT22204A INS22205 AINS214–216 EPEFrameshift (insertion)S gene
T22673C C22674TS371LNonsynonymousS gene
T22882GN440KNonsynonymousS gene
G22898AG446SNonsynonymousS gene
T22679CS373PNonsynonymousS gene
G22813TK417NNonsynonymousS geneNot detected in one (EPI_ISL_8182845) variant
Δ6513–6515 ΔGTTΔ2083 S L2084IFrameshift (deletion)ORF1a/bNot and detected EPI_ISL_in 6647956two variants ) (EPI-ISL-6640916
A27259C SynonymousM genNot detected in two variants (EPI_ISL_6647956 and (EPI_ISL_8182845)
G22992AS477NNonsynonymousS geneNot detected in three variants(EPI_ISL_6647956, EPI_ISL_6647957 and EPI_ISL_8182845)
A23013CE484ANonsynonymousS gene
A23040GQ493RNonsynonymousS gene
G23048AG496SNonsynonymousS gene
A23055GQ498RNonsynonymousS gene

Mutations shared between Omicron and other VOCs.

Nucleotide mutationmutation ProteinType of mutationGeneComment
Δ21767-21769 ΔCATΔ69HFrameshift (deletion)S geneShared with Alpha variant (EPI_ISL_6756515)
Δ21770 ΔGΔ70VFrameshift (deletion)S gene
C23525TH655YNonsynonymousS geneShared with Gamma variant (EPI_ISL_6228367)
C10029TT3255INonsynonymousORF1a/bShared with Delta (EPI_ISL_6832166)
C21846TT95INonsynonymousS geneand Mu (EPI_ISL_4470504) variants
C23604AP681HNonsynonymousS geneShared and Mu with (EPI_Alpha ISL_(4470504EPI_ISL_) 6756515variants )
G28881TR203KNonsynonymousN geneShared with Alpha (EPI_ISL_6756515)
G28882A SynonymousN geneand Gamma (EPI_ISL_6228367) variants
G28883CG204RNonsynonymousN gene
C22995AT478KNonsynonymousS geneShared with Delta (EPI_ISL_6832166) variant
A23063TN501YNonsynonymousS geneShared with Alpha (EPI_ISL_6756515), Beta (EPI_ISL_5416540), Gamma (EPI_ISL_6228367), Mu (EPI_ISL_4470504), variants

The mutations among Omicron variants were categorized into three groups; the unique common mutations group which involved 50.8% (31/61) of the mutations (Table II); the unique non-common mutations group, which involved 31.1% (19/61) of the mutations (Table III), and the shared mutations group which involved 18.0% (11/61) of the mutations (Table IV). The unique common mutations characterized and differentiated Omicron variants from the other VOCs. These mutations were present only in Omicron variants, unique non-common mutations were also associated with Omicron variants but were absent in all variants, while the shared mutations existed in Omicron as well the other VOCs. Most of the unique common mutations 54.8% (17/31) were non-synonymous mutations, followed by 29% (9/31) frameshift deletions, which were observed in the S gene 55.6% (5/9) and in the N gene 44.4% (4/9) (Table II and Fig. 1).

Similarly, many unique non-common mutations (12/19, 63.2%) were non-synonymous. Some of them (3/19, 15.8%) were frameshift deletions and (1/19, 5.3%) frameshift insertions (Table III and Fig. 1). Interestingly the frameshift insertion (Ins22194, T22195G) led to frameshift deletion (Δ211N) (Table III and Fig. 1).

All Omicron variants showed frameshift deletions in the S and N genes and ORF1a/b except (EPI_ISL_ 6647956) variant, which did not show deletion in the ORF1a/b. All Omicron variants showed frameshift insertion in the S gene except (EPI_ISL_8182845) variant. The Alpha, Beta, and Gamma variants showed frameshift deletions in ORF1a/b, while the Mu variant showed frameshift insertion in the S gene.

Furthermore, 11 mutations were shared between Omicron variants and other VOCs (Alpha, Beta, Delta, Gamma, and Mu); 63.6% (7/11) of these mutations occurred on the S gene, 18.2% (2/11) were frameshift deletion (Δ21767-21769 ΔCAT (Δ69H) and Δ21770 ΔG (Δ70V)) that were shared with Alpha variant and three mutations in the N gene; G28881T (R203K), G28882A, G28883C (G204R) shared with Alpha (EPI_ISL_6756515) and Gamma (EPI_ISL_6228367) variants, one mutation occurred in ORF1a/b C10029T (T3255I) shared with Delta (EPI_ISL_6832166) and Mu (EPI_ISL_4470504) variants. The mutation A23063T (N501Y) in the S gene was shared with Alpha (EPI_ ISL_6756515), Beta (EPI_ISL_5416540), Gamma (EPI_ ISL_6228367), Mu (EPI_ISL_4470504), and Omicron variants (EPI_ISL_8182845, EPI_ISL_6647961, EPI_ ISL_7740798, EPI-ISL-6640916) (Table IV and Fig. 1).

Fig. 1

The genomic landscape representing nucleotides changes for variants of concerns of SARS-CoV-2 and corresponding amino acid changes.

A phylogenetic relationship between Omicron variants, Wuhan reference, and certain variants of concerns revealed two distinct clads of Omicron: one at the top and one at the bottom of the evolutionary tree (Fig. 2).

Fig. 2

Phylogenetic affiliation for variants of concerns of SARS-CoV-2.

Discussion

Omicron variants showed too many mutations compared to the previously evolved variants of concern (Kannan et al. 2021), which is why it has been described as a “worrying type”. These mutations may alter the virus’s conformation and affect the capacity for immune evasion, disease severity, and transmissibility (Zhang et al. 2021). However, the information about the Omicron variants is limited (Kannan et al. 2022).

The present study displayed that most of the mutations (60.5%) among the VOCs were non-synonymous mutations that occurred mainly in the S gene. This finding was contradictory to our earlier reports at the beginning of this pandemic, in which we found that most mutations occurred in ORF1a/b (Ahmed-Abakur and Alnour 2020). Several other authors stated that ORF1a/b was occupied with more than 60% of mutations (Khailany et al. 2020; Shishir et al. 2021). The recent reports approved that the principal mechanism of SARS-CoV-2 evolution is natural selection, so the heavy mutations in the S gene could be attributed to the breakthrough of the SARS-CoV-2 vaccine. Wang et al. 2021 proposed that vaccine breakthroughs will become a major mechanism of SARS-CoV-2 evolution as most of the population is either infected or vaccinated.

Our study showed 61 amino acid mutations among Omicron variants; 31 of 61 (50.8%) were unique common mutations, 19 of 61 (31.1%) were unique non-common mutations, and 11 of 61 (18%) were shared mutations. These results reflected a high occurrence of mutations among the Omicron variants under the study compared to the most published reports that indicated 47 to 58 mutations in Omicron variants (Jia et al. 2022; Poudel et al. 2022; Tan et al. 2022; Thakur and Ratho 2022). Kannan et al. (2022) studied the unique features of the Omicron variant and reported 46 mutations, 23 of which were unique to the Omicron variant. Jia et al. (2022) and Kannan et al. (2022) mentioned that some Omicron signature mutations might not be present in some variants, similar to our finding concerning the unique non-common mutations.

The present study showed that only four common mutations were present in all the VOCs; one silent mutation (C241T) in the 5’UTR region, one synonymous mutation (C3037T) in ORF1, one non-synonymous mutation in ORF1a/b (C14408T) which changed the amino acid (P4715L), and one non-synonymous mutation in the S gene (A23403G) changing the amino acid (D614G). These findings showed the importance and role of these four mutations. We propose that they have become part of each circulating variant of SARS-CoV-2. Although the mutations (C241T) and (C3037T) do not affect protein structure or function, they may support the virus to cloak itself within the host or affect transmission. The (C14408T) might influence the replication rate; it altered the amino acid in RNA-dependent RNA polymerase (Ahmed-Abakur et al. 2022). The (D614G) mutation occurred in the S2 domain, which is important for the fusion of the spike protein with the host cell membrane, thus may increase the infectivity and spread of the virus (Callaway 2021; Quarleri et al. 2022). Corresponding to this finding, Korber et al. (2020) reported that SARS-CoV-2 carrying the mutation D614G has become the dominant form. However, many reports showed the co-existence of C241T, C3037T, C14408T, and A23403G (Ahmed-Abakur et al. 2022; Kandeel et al. 2022; Kumar et al. 2022).

Our study showed 14 frameshift deletions (nine in the unique common mutations group, three in the unique non-common mutations group, and two in the shared mutations group) and two frameshift insertions. A higher number of deletions and insertions were reported by Tan et al. (2022), who characterized the first two cases of the Omicron variant in China. They showed 39 deletions and nine insertions. The CDC (2021) stated that the Omicron variant (B.1.1.529) has one tiny insertion and three small deletions in the spike glycoprotein Δ69‐70 Δ143‐145, Δ211 (28). The previously mentioned frameshift affected five amino acids that were Δ69H, Δ70V, Δ143V, Δ144Y, and Δ145Y. In addition to these deletions, our study pointed out nine frameshift deletions more: three in the S gene (A67V, G142D, and Δ211N), four in the N gene (Δ31E, Δ32R, Δ33S, and one synonymous), and two in ORF1a/b (Δ3674-3676 ΔLSG and Δ2083S L2084I). Thakur and Ratho (2022) reported that the deletions at positions H69‐ and V70‐ result in failure of the S‐gene target. Recently, some studies proposed that the SARS-CoV-2 spike protein insertion sequences may be derived from either host or other coronaviruses. These findings might have subsequently affected the viral entry and failure of antibodies to deactivate this variant (Kannan et al. 2022).

The present study exhibited heavy mutations in the S gene compared to the previous studies; several authors figured out 30–32 mutations in the S gene of Omicron variants, one minor insertion, and three deletions (Karim and Karim 2021; Zhang et al. 2021; Gao et al. 2022; Gowrisankar et al. 2022; Kumar et al 2022;). However, our study showed that 34.2% (13/38) of the mutations in the S gene occurred in the receptor-binding domain (RBD). This site (RBD) is important for the entry of SARS-CoV-2, represents the binding site to the host receptor (ACE2), and is the main target of antibodies and therapeutics agents (Hu et al. 2022). Therefore, mutations at this site mainly affected the transmission, efficiency of the available vaccine, and treatment. In alignment with our findings, Zhang et al. (2021) mentioned that Q498R, Q493K, G496S, S477N, G446S, N440K, S375F, S373P, S371, and G339D were the new mutations in the RBD of Omicron variants. They concluded that the mutation on the receptor-binding motif leads to conformational changes that may potentiate the ability of immune evasion. Also, Lupala et al. 2022 found that most of the mutations on RBD were located at the RBD-ACE2 interface. Subsequently, these mutations alter the electrostatic charges at the interface which affects the binding of neutralizing antibodies and medications targeting the interface (Zhang et al. 2021; Mohapatra et al. 2022; Saxena et al. 2022). The modification at the RBD-ACE2 interface increases the binding through increasing buried solvent accessible surface area and enhancing the hydrogen bonding interaction (Lupala et al. 2022). Similarly, Andreata-Santos et al. (2022) stated that the mutations G142D and P681H corresponded to vital regions targeted by neutralizing antibodies. Kannan et al. (2021) reported that N501Y, Q493R, E484A, and T478K were the vital mutations in the RBM. The mutation T478K was also found in Delta variants, and it was linked to infections of vaccinated people (Zhang et al. 2021). Likewise, the mutation in 484 was observed in Gamma and Beta variants and associated with the reinfection with the Gamma variant (Kannan et al. 2021), where the glutamic acid is replaced by lysine (E484K). Interestingly, in the Omicron variant, it is replaced by alanine (E484A). The mutation E484A might modify the interaction between human angiotensin-converting hACE2 and RBD. The mutation N501Y was detected earlier in the Gamma, Beta, and Alpha variants and was recognized as having a strong affinity to hACE2 (CDC 2021).

However, Karim and Karim (2021) reported that most Omicron mutations’ effects are unknown, leading to uncertainty about how these mutation combinations could affect the response to natural and acquired immunity. Poudel et al. (2022) mentioned that only twelve mutations were studied in the past, and it is early to realize the new mutations and how they affect the virus behavior.

The mutations in the ORF1a/b gene in the present study were almost matched with the results by Thakur and Ratho (2022), who reported that the mutations in ORF1a/b compromise the cell’s capability to destroy viral components and therefore assist in the evasion of innate immunity. The mutations in the E gene in our study were in alignment with Saxena et al. (2022) and Kannan et al. (2021). Opposite to our results for the M gene, numerous reports showed two non-synonymous mutations (D3G and Q19E) and one synonymous mutation (A63T) (Kannan et al. 2021; Saxena et al. 2022; Thakur and Ratho 2022). The changings in the N gene in our study matched with Kannan et al. (2021), Saxena et al. (2022), and Thakur and Ratho (2022), concerning the non-synonymous mutations (P13L, N: R203K, and N: G204R). Moreover, Saxena et al. (2022) showed one deletion (Δ31‐33). In addition to the previous mutations, we pointed out four frameshift deletions (Δ28363-28364 ΔGA, Δ31E, Δ32R, Δ33S), and one synonymous G28882A.

Our study showed that 11 mutations were shared between Omicron and other VOCs; N501Y was the most common mutation; it appeared in Omicron, Alpha, Beta, Gamma, and Mu. T3255I and T95I were shared with Delta, Mu, and Omicron. The deletions Δ69H and Δ70V were observed in Alpha and Omicron variants. T478K appeared in Omicron and Delta. R203K, G204R, and the synonymous mutation G28882A were found in Alpha, Gamma, and Omicron variants. However, numerous other mutations have been reported by other authors, such as Lys38Arg, SΔ1265, Leu1266Ile, Ala1892Thr, Thr492Ile, Phe132His, Δ105‐107, Ile189Val, Pro323Leu NSP14‐Ile42Val (Saxena et al. 2022). P3395H, S3675‐, G3676- (Thakur and Ratho 2022). T492I, P314L, P323L (Kannan et al. 2021). L141F, R346K, V367F 5 L455, P499, A475 and F486 (Yi et al.2020).

The phylogenetic tree in our study showed two distinct clads of Omicron; one at the top and one at the bottom. Such a pattern is as arduous to explain as the Omicron origin and its higher number of mutations within a limited time frame compared to the original SARS-CoV-2 and its other variants. Nonetheless, the three sub-lineages of Omicron have been reported to be sufficiently distinct (Mahase 2022). It might be presumed that the Omicron has originated from an early lineage of wild-type SARS-CoV-2 and subsequently, its sub-lineages evolved independently in an unmonitored environment which was not traced in the reservoir population somewhere in the world until it became dominant with the steady weakening of other VOCs due to herd, vaccine-induced or hybrid immunity (Mallapaty 2022). Moreover, a study by Wang and Cheng (2022) analyzed the sequence of Omicron variants in South Africa and reported two subclades based on the sequence of spike genes.

Indeed, the impact of this variant had been reported to be high as incidence of Omicron infections increased exponentially in various affected regions such as South Africa, United Kingdom, and USA, which in a short-span overtook the delta variant, thus implying that the variant was highly transmissible (Sharma et al. 2022). Interestingly, the variant emerged when the vaccine breakthrough was already achieved (Rauf et al. 2022). As mentioned, spike proteins which are the target of vaccine immunity were found to be heavily mutated in the variant. Various comparative studies emerged suggesting new approaches to target viral-host molecular interactions and evolve preventive strategies (Isidoro et al 2022; Vardhan and Sahoo 2022a; 2022b).

Conclusions

The present study confirmed that the majority of mutations developed by Omicron variants occurred in the vaccine target gene (S gene) and most of the mutations in the receptor-binding domain occurred in the receptor-binding motif. Thus, we propose that the vaccine breakthrough has the potential to affect the genetic evolution of SARS-CoV-2.

Future perspectives

The inevitable stress caused by the COVID-19 disease globally, with the loss of human lives, post-COVID-19 mental and physical health issues, and disturbing social cohesion and economic failure has been an unprecedented incidence in recent times. Henceforth in a short time, enormous experimental research and meta-analyses have brought forward a bulk of studies that facilitated the determination of viral genomic landscape, sources and mode of viral transmission, pathogenesis, preventive strategies, and acquired immunity through vaccines. Our study is a significant piece of work that has the potential to be used as a reference in the future for the evolutionary genetics of SARS-CoV-2 and relate to any further risk of emerging variants and abeyant COVID-19 waves.

Fig. 1

The genomic landscape representing nucleotides changes for variants of concerns of SARS-CoV-2 and corresponding amino acid changes.
The genomic landscape representing nucleotides changes for variants of concerns of SARS-CoV-2 and corresponding amino acid changes.

Fig. 2

Phylogenetic affiliation for variants of concerns of SARS-CoV-2.
Phylogenetic affiliation for variants of concerns of SARS-CoV-2.

The unique non-common mutations among Omicron variants.

Nucleotide mutation Protein mutation Type of mutation Gene Comment
C24503T L981F Nonsynonymous S gene Not detected in (EPI-ISL-6640916) variant
ΔΔGTTTGTCTG 11283–1129 Δ3674–3676 ΔLSG Frameshift (deletion) ORF1a/b Not detected in variant (EPI_ISL_6647956)
C27807T Synonymous ORF7b Not detected in (EPI_ISL_8182845) variant
T13195C synonymous ORF1a/b Not detected in one (EPI_ISL_8182845) variant
Ins22194T T22195G Δ211N Frameshift (deletion) S gene
T22197G A22198C L212I Nonsynonymous S gene
INS22202–22203 AGINS22203–22204 CAT22204A INS22205 A INS214–216 EPE Frameshift (insertion) S gene
T22673C C22674T S371L Nonsynonymous S gene
T22882G N440K Nonsynonymous S gene
G22898A G446S Nonsynonymous S gene
T22679C S373P Nonsynonymous S gene
G22813T K417N Nonsynonymous S gene Not detected in one (EPI_ISL_8182845) variant
Δ6513–6515 ΔGTT Δ2083 S L2084I Frameshift (deletion) ORF1a/b Not and detected EPI_ISL_in 6647956two variants ) (EPI-ISL-6640916
A27259C Synonymous M gen Not detected in two variants (EPI_ISL_6647956 and (EPI_ISL_8182845)
G22992A S477N Nonsynonymous S gene Not detected in three variants(EPI_ISL_6647956, EPI_ISL_6647957 and EPI_ISL_8182845)
A23013C E484A Nonsynonymous S gene
A23040G Q493R Nonsynonymous S gene
G23048A G496S Nonsynonymous S gene
A23055G Q498R Nonsynonymous S gene

Distribution and type of mutations among variants of concern of SARS-CoV-2.

of mutation Type 3’UTR ORF10 N gene ORF8 ORF7b ORF7a ORF6 M gene E gene ORF3 S gene ORFa/b1 5’UTR Total
Non-coding 2 3 5
Non- synonymous 11 6 1 3 4 2 5 52 43 127
Synonymous  5 1 1 1 1 2  4 36 51
Frame shift/insertion  1  3 4
Frame shift/deletion  4 15 3 22
Nonsense 1 1
2 21 8 2 3 1 4 3 7 74 82 3 210

Mutations shared between Omicron and other VOCs.

Nucleotide mutation mutation Protein Type of mutation Gene Comment
Δ21767-21769 ΔCAT Δ69H Frameshift (deletion) S gene Shared with Alpha variant (EPI_ISL_6756515)
Δ21770 ΔG Δ70V Frameshift (deletion) S gene
C23525T H655Y Nonsynonymous S gene Shared with Gamma variant (EPI_ISL_6228367)
C10029T T3255I Nonsynonymous ORF1a/b Shared with Delta (EPI_ISL_6832166)
C21846T T95I Nonsynonymous S gene and Mu (EPI_ISL_4470504) variants
C23604A P681H Nonsynonymous S gene Shared and Mu with (EPI_Alpha ISL_(4470504EPI_ISL_) 6756515variants )
G28881T R203K Nonsynonymous N gene Shared with Alpha (EPI_ISL_6756515)
G28882A Synonymous N gene and Gamma (EPI_ISL_6228367) variants
G28883C G204R Nonsynonymous N gene
C22995A T478K Nonsynonymous S gene Shared with Delta (EPI_ISL_6832166) variant
A23063T N501Y Nonsynonymous S gene Shared with Alpha (EPI_ISL_6756515), Beta (EPI_ISL_5416540), Gamma (EPI_ISL_6228367), Mu (EPI_ISL_4470504), variants

The unique common mutations among Omicron variants.

Nucleotide Mutation Protein mutation Type of mutation Gene
A2832G K856R Nonsynonymous ORF1a/b
3T5386G Synonymous ORF1a/b
G8393A A2710T Nonsynonymous ORF1a/b
C10449A Synonymous ORF1a/b
A11537G I3758V Nonsynonymous ORF1a/b
C15240T Synonymous ORF1a/b
A18163G I5968V Nonsynonymous ORF1a/b
ΔΔ21762 21764 ΔC ΔA A67V Frameshift (deletion) S gene
Δ21767–21769 ΔCAT Δ69H Frameshift (deletion) S gene
Δ21770 ΔG Δ70V Frameshift (deletion) S gene
Δ21987–21988 ΔGT G142D Frameshift (deletion) S gene
Δ21989–21991 ΔGTT Δ143V Frameshift (deletion) S gene
Δ21992–21994 ΔTAT Δ144Y Frameshift (deletion) S gene
Δ21995 ΔG Δ145Y Frameshift (deletion) S gene
G22578A G339D Nonsynonymous S gene
C23202A T547K Nonsynonymous S gene
C23525T H655Y Nonsynonymous S gene
T23599G N679K Nonsynonymous S gene
C23854A N764K Nonsynonymous S gene
G23948T D796Y Nonsynonymous S gene
C24130A N856K Nonsynonymous S gene
A24424T Q954H Nonsynonymous S gene
T24469A N969K Nonsynonymous S gene
C25000T Synonymous S gene
C25584T Synonymous ORF3a
C26270T T9I Nonsynonymous E gene
A26530G D3G Nonsynonymous M gene
G26709A A63T Nonsynonymous M gene
C28311T P13L Nonsynonymous N gene
Δ28363–28364 ΔGA Frameshift (deletion) N gene
Δ28365–28367 ΔGAA Δ31E Frameshift (deletion) N gene
Δ28368–28370 ΔCGC Δ32R Frameshift (deletion) N gene
Δ28371 ΔA Δ33S Frameshift (deletion) N gene

Adiga R, Nayak V. Emergence of novel SARS-CoV-2 variants in India: second wave. J Infect Dev Ctries. 2021 Nov;15(11):1578–1583. https://doi.org/10.3855/jidc.15484Adiga R Nayak V Emergence of novel SARS-CoV-2 variants in India: second wave J Infect Dev Ctries 2021 Nov15111578 1583 https://doi.org/10.3855/jidc.1548410.3855/jidc.1548434898481Search in Google Scholar

Ahmed-Abakur EH, Alnour TMS. Genetic variations among SARS-CoV-2 strains isolated in China. Gene Rep. 2020 Dec;21:100925. https://doi.org/10.1016/j.genrep.2020.100925Ahmed-Abakur EH Alnour TMS Genetic variations among SARS-CoV-2 strains isolated in China Gene Rep 2020 Dec21100925 https://doi.org/10.1016/j.genrep.2020.10092510.1016/j.genrep.2020.100925783452033521384Search in Google Scholar

Ahmed-Abakur EH, Ullah MF, Elssaig EH, Alnour TMS. In-silico genomic landscape characterization and evolution of SARS-CoV-2 variants isolated in India shows significant drift with high frequency of mutations. Saudi J Biol Sci. 2022 May;29(5):3494–3501. https://doi.org/10.1016/j.sjbs.2022.02.030Ahmed-Abakur EH Ullah MF Elssaig EH Alnour TMS In-silico genomic landscape characterization and evolution of SARS-CoV-2 variants isolated in India shows significant drift with high frequency of mutations Saudi J Biol Sci 2022 May2953494 3501 https://doi.org/10.1016/j.sjbs.2022.02.03010.1016/j.sjbs.2022.02.030887576635233173Search in Google Scholar

Andreata-Santos R, Janini LMR, Durães-Carvalho R. From Alpha to Omicron SARS‑CoV‑2 variants: what their evolutionary signatures can tell us? J Med Virol. 2022 May;94(5):1773–1776. https://doi.org/10.1002/jmv.27555Andreata-Santos R Janini LMR Durães-Carvalho R From Alpha to Omicron SARS‑CoV‑2 variants: what their evolutionary signatures can tell us? J Med Virol 2022 May9451773 1776 https://doi.org/10.1002/jmv.2755510.1002/jmv.27555901555834978091Search in Google Scholar

Callaway E. Beyond Omicron: what’s next for COVID’s viral evolution. Nature. 2021 Dec;600(7888):204–207. https://doi.org/10.1038/d41586-021-03619-8Callaway E Beyond Omicron: what’s next for COVID’s viral evolution Nature 2021 Dec6007888204 207 https://doi.org/10.1038/d41586-021-03619-810.1038/d41586-021-03619-834876665Search in Google Scholar

Cao C, Cai Z, Xiao X, Rao J, Chen J, Hu N, Yang M, Xing X, Wang Y, Li M, et al. The architecture of the SARS-CoV-2 RNA genome inside virion. Nat Commun. 2021 Jun;12(1):3917. https://doi.org/10.1038/s41467-021-22785-xCao C Cai Z Xiao X Rao J Chen J Hu N Yang M Xing X Wang Y Li M et al The architecture of the SARS-CoV-2 RNA genome inside virion Nat Commun 2021 Jun1213917 https://doi.org/10.1038/s41467-021-22785-x10.1038/s41467-021-22785-x822578834168138Search in Google Scholar

CDC. Science brief: Omicron (B.1.1.529) variant [Internet]. Atlanta (USA): Centers for Disease Control and Prevention; 2021 [cited 2022 Mar 18]. Available from https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-Omicron-variant.htmlCDC Science brief: Omicron (B.1.1.529) variant [Internet] Atlanta (USA) Centers for Disease Control and Prevention; 2021 [cited 2022 Mar 18]. Available from https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-Omicron-variant.htmlSearch in Google Scholar

Choi JY, Smith DM. SARS-CoV-2 variants of concern. Yonsei Med J. 2021 Nov;62(11):961–968. https://doi.org/10.3349/ymj.2021.62.11.961Choi JY Smith DM SARS-CoV-2 variants of concern Yonsei Med J 2021 Nov6211961 968 https://doi.org/10.3349/ymj.2021.62.11.96110.3349/ymj.2021.62.11.961854247434672129Search in Google Scholar

Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution. 1985 Jul;39(4):783–791. https://doi.org/10.1111/j.1558-5646.1985.tb00420.xFelsenstein J Confidence limits on phylogenies: an approach using the bootstrap Evolution 1985 Jul394783 791 https://doi.org/10.1111/j.1558-5646.1985.tb00420.x10.1111/j.1558-5646.1985.tb00420.x28561359Search in Google Scholar

Gao SJ, Guo H, Luo G. Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert! J Med Virol. 2022 Apr; 94(4): 1255–1256. https://doi.org/10.1002/jmv.27491Gao SJ Guo H Luo G Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert! J Med Virol 2022 Apr 944 1255 1256 https://doi.org/10.1002/jmv.2749110.1002/jmv.27491901539734850421Search in Google Scholar

Gowrisankar A, Priyanka TMC, Banerjee S. Omicron: a mysterious variant of concern. Eur Phys J Plus. 2022;137(1):100. https://doi.org/10.1140/epjp/s13360-021-02321-yGowrisankar A Priyanka TMC Banerjee S Omicron: a mysterious variant of concern Eur Phys J Plus 20221371100 https://doi.org/10.1140/epjp/s13360-021-02321-y10.1140/epjp/s13360-021-02321-y874375035036269Search in Google Scholar

Gu H, Krishnan P, Ng DYM, Chang LDJ, Liu GYZ, Cheng SSM, Hui MMY, Fan MCY, Wan JHL, Lau LHK, et al. Probable transmission of SARS-CoV-2 Omicron variant in quarantine hotel, Hong Kong, China, November 2021. Emerg Infect Dis. 2022 Feb; 28(2): 460–462. https://doi.org/10.3201/eid2802.212422Gu H Krishnan P Ng DYM Chang LDJ Liu GYZ Cheng SSM Hui MMY Fan MCY Wan JHL Lau LHK et al Probable transmission of SARS-CoV-2 Omicron variant in quarantine hotel, Hong Kong, China, November 2021 Emerg Infect Dis 2022 Feb 282 460 462 https://doi.org/10.3201/eid2802.21242210.3201/eid2802.212422879867834860154Search in Google Scholar

Hu J, Peng P, Cao X, Wu K, Chen J, Wang K, Tang N, Huang AL. Increased immune escape of the new SARS-CoV-2 variant of concern Omicron. Cell Mol Immunol. 2022 Feb;19(2):293–295. https://doi.org/10.1038/s41423-021-00836-zHu J Peng P Cao X Wu K Chen J Wang K Tang N Huang AL Increased immune escape of the new SARS-CoV-2 variant of concern Omicron Cell Mol Immunol 2022 Feb192293 295 https://doi.org/10.1038/s41423-021-00836-z10.1038/s41423-021-00836-z874934735017716Search in Google Scholar

Isidoro C, Chiung-Fang Chang A, Sheen LY. Natural products as a source of novel drugs for treating SARS-CoV2 infection. J Tradit Complement Med. 2022 Jan;12(1):1–5. https://doi.org/10.1016/j.jtcme.2022.02.001Isidoro C Chiung-Fang Chang A Sheen LY Natural products as a source of novel drugs for treating SARS-CoV2 infection J Tradit Complement Med 2022 Jan1211 5 https://doi.org/10.1016/j.jtcme.2022.02.00110.1016/j.jtcme.2022.02.001882297035155135Search in Google Scholar

Jia H, Wang H, Cao L, Lai Z, Cheng Z, Chen Q, Liu T, Liu X, Wen Y, Xu C, et al. Genetic analysis of a SARS-CoV-2 Omicron variant from a Chinese traveller returning from overseas. Emerg Microbes Infect. 2022 Dec;11(1):306–309. https://doi.org/10.1080/22221751.2022.2025747Jia H Wang H Cao L Lai Z Cheng Z Chen Q Liu T Liu X Wen Y Xu C et al Genetic analysis of a SARS-CoV-2 Omicron variant from a Chinese traveller returning from overseas Emerg Microbes Infect 2022 Dec111306 309 https://doi.org/10.1080/22221751.2022.202574710.1080/22221751.2022.2025747882079534983331Search in Google Scholar

Kandeel M, Mohamed MEM, Abd El-Lateef HM, Venugopala KN, El-Beltagi HS. Omicron variant genome evolution and phylogenetics. J Med Virol. 2022 Apr;94(4):1627–1632. https://doi.org/10.1002/jmv.27515Kandeel M Mohamed MEM Abd El-Lateef HM Venugopala KN El-Beltagi HS Omicron variant genome evolution and phylogenetics J Med Virol 2022 Apr9441627 1632 https://doi.org/10.1002/jmv.2751510.1002/jmv.27515901534934888894Search in Google Scholar

Kannan S, Shaik Syed Ali P, Sheeza A. Omicron (B.1.1.529) – variant of concern – molecular profile and epidemiology: a mini review. Eur Rev Med Pharmacol Sci. 2021 Dec;25(24):8019–8022. https://doi.org/10.26355/eurrev_202112_27653Kannan S Shaik Syed Ali P Sheeza A Omicron (B.1.1.529) – variant of concern – molecular profile and epidemiology: a mini review Eur Rev Med Pharmacol Sci 2021 Dec25248019 8022 https://doi.org/10.26355/eurrev_202112_27653Search in Google Scholar

Kannan SR, Spratt AN, Sharma K, Chand HS, Byrareddy SN, Singh K. Omicron SARS‑CoV-2 variant: unique features and their impact on pre-existing antibodies. J Autoimmun. 2022 Jan;126: 102779. https://doi.org/10.1016/j.jaut.2021.102779Kannan SR Spratt AN Sharma K Chand HS Byrareddy SN Singh K Omicron SARS‑CoV-2 variant: unique features and their impact on pre-existing antibodies J Autoimmun 2022 Jan126 102779 https://doi.org/10.1016/j.jaut.2021.10277910.1016/j.jaut.2021.102779866630334915422Search in Google Scholar

Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet. 2021 Dec;398(10317): 2126–2128. https://doi.org/10.1016/S0140-6736(21)02758-6Karim SSA Karim QA Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic Lancet 2021 Dec39810317 2126 2128 https://doi.org/10.1016/S0140-6736(21)02758-610.1016/S0140-6736(21)02758-6864067334871545Search in Google Scholar

Khailany RA, Safdar M, Ozaslan M. Genomic characterization of a novel SARS-CoV-2. Gene Rep. 2020 Jun;19:100682. https://doi.org/10.1016/j.genrep.2020.100682Khailany RA Safdar M Ozaslan M Genomic characterization of a novel SARS-CoV-2 Gene Rep 2020 Jun19100682 https://doi.org/10.1016/j.genrep.2020.10068210.1016/j.genrep.2020.100682716148132300673Search in Google Scholar

Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner N, Giorgi EE, Bhattacharya T, Foley B, et al; Sheffield COVID-19 Genomics Group. Tracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020 Aug;182(4):812–827.e19. https://doi.org/10.1016/j.cell.2020.06.043Korber B Fischer WM Gnanakaran S Yoon H Theiler J Abfalterer W Hengartner N Giorgi EE Bhattacharya T Foley B et al; Sheffield COVID-19 Genomics Group Tracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 virus Cell 2020 Aug1824812 827e19 https://doi.org/10.1016/j.cell.2020.06.04310.1016/j.cell.2020.06.043733243932697968Search in Google Scholar

Kumar S, Thambiraja TS, Karuppanan K, Subramaniam G. Omicron and Delta variant of SARS-CoV-2: a comparative computational study of spike protein. J Med Virol. 2022 Apr;94(4):1641–1649. https://doi.org/10.1002/jmv.27526Kumar S Thambiraja TS Karuppanan K Subramaniam G Omicron and Delta variant of SARS-CoV-2: a comparative computational study of spike protein J Med Virol 2022 Apr9441641 1649 https://doi.org/10.1002/jmv.2752610.1002/jmv.2752634914115Search in Google Scholar

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb;395(10224):565–574. https://doi.org/10.1016/S0140-6736(20)30251-8Lu R Zhao X Li J Niu P Yang B Wu H Wang W Song H Huang B Zhu N et al Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Lancet 2020 Feb39510224565 574 https://doi.org/10.1016/S0140-6736(20)30251-810.1016/S0140-6736(20)30251-8715908632007145Search in Google Scholar

Lupala CS, Ye Y, Chen H, Su XD, Liu H. Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor. Biochem Biophys Res Commun. 2022 Jan;590:34–41. https://doi.org/10.1016/j.bbrc.2021.12.079Lupala CS Ye Y Chen H Su XD Liu H Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor Biochem Biophys Res Commun 2022 Jan59034 41 https://doi.org/10.1016/j.bbrc.2021.12.07910.1016/j.bbrc.2021.12.079870263234968782Search in Google Scholar

Mahase E. Covid-19: What do we know about omicron sublineages? BMJ. 2022 Feb;376:o358. https://doi.org/10.1136/bmj.o358Mahase E Covid-19: What do we know about omicron sublineages? BMJ 2022 Feb376o358 https://doi.org/10.1136/bmj.o35810.1136/bmj.o35835149516Search in Google Scholar

Mallapaty S. Where did Omicron come from? Three key theories. Nature. 2022 Feb;602(7895):26–28. https://doi.org/10.1038/d41586-022-00215-2Mallapaty S Where did Omicron come from? Three key theories Nature 2022 Feb602789526 28 https://doi.org/10.1038/d41586-022-00215-210.1038/d41586-022-00215-235091701Search in Google Scholar

Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira IATM, Datir R, Collier DA, Albecka A, Singh S, et al.; Indian SARS-CoV-2 Genomics Consortium (INSACOG); Genotype to Phenotype Japan (G2P-Japan) Consortium; CITIID-NIHR BioResource COVID-19 Collaboration. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021 Nov;599(7883): 114–119. https://doi.org/10.1038/s41586-021-03944-yMlcochova P Kemp SA Dhar MS Papa G Meng B Ferreira IATM Datir R Collier DA Albecka A Singh S et al Indian SARS-CoV-2 Genomics Consortium (INSACOG); Genotype to Phenotype Japan (G2P-Japan) Consortium; CITIID-NIHR BioResource COVID-19 Collaboration. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion Nature 2021 Nov5997883 114 119 https://doi.org/10.1038/s41586-021-03944-y10.1038/s41586-021-03944-y856622034488225Search in Google Scholar

Mohapatra RK, Sarangi AK, Kandi V, Azam M, Tiwari R, Dhama K. Omicron (B.1.1.529 variant of SARS-CoV-2); an emerging threat: current global scenario. J Med Virol. 2022 May;94(5):1780–1783. https://doi.org/10.1002/jmv.27561Mohapatra RK Sarangi AK Kandi V Azam M Tiwari R Dhama K Omicron (B.1.1.529 variant of SARS-CoV-2); an emerging threat: current global scenario J Med Virol 2022 May9451780 1783 https://doi.org/10.1002/jmv.2756110.1002/jmv.27561901545434964506Search in Google Scholar

Poudel S, Ishak A, Perez-Fernandez J, Garcia E, León-Figueroa DA, Romaní L, Bonilla-Aldana DK, Rodriguez-Morales AJ. Highly mutated SARS-CoV-2 Omicron variant sparks significant concern among global experts – what is known so far? Travel Med Infect Dis. 2022 Jan-Feb;45:102234. https://doi.org/10.1016/j.tmaid.2021.102234Poudel S Ishak A Perez-Fernandez J Garcia E León-Figueroa DA Romaní L Bonilla-Aldana DK Rodriguez-Morales AJ Highly mutated SARS-CoV-2 Omicron variant sparks significant concern among global experts – what is known so far? Travel Med Infect Dis 2022 Jan-Feb45102234 https://doi.org/10.1016/j.tmaid.2021.10223410.1016/j.tmaid.2021.102234866666234896326Search in Google Scholar

Quarleri J, Galvan V, Delpino MV. Omicron variant of the SARS-CoV-2: a quest to define the consequences of its high mutational load. Geroscience. 2022 Feb;44(1):53–56. https://doi.org/10.1007/s11357-021-00500-4Quarleri J Galvan V Delpino MV Omicron variant of the SARS-CoV-2: a quest to define the consequences of its high mutational load Geroscience 2022 Feb44153 56 https://doi.org/10.1007/s11357-021-00500-410.1007/s11357-021-00500-4868330934921354Search in Google Scholar

Rauf A, Abu-Izneid T, Khalil AA, Hafeez N, Olatunde A, Rahman M, Semwal P, Al-Awthan YS, Bahattab OS, Khan IN, et al. Nanoparticles in clinical trials of COVID-19: an update. Int J Surg. 2022 Aug;104:106818. https://doi.org/10.1016/j.ijsu.2022.106818Rauf A Abu-Izneid T Khalil AA Hafeez N Olatunde A Rahman M Semwal P Al-Awthan YS Bahattab OS Khan IN et al Nanoparticles in clinical trials of COVID-19: an update Int J Surg 2022 Aug104106818 https://doi.org/10.1016/j.ijsu.2022.10681810.1016/j.ijsu.2022.106818935976935953020Search in Google Scholar

Rudrapal M, Khairnar SJ, Borse LB, Jadhav AG. Coronavirus Disease-2019 (COVID-19): an updated review. Drug Res (Stuttg). 2020 Sep;70(9):389–400. https://doi.org/10.1055/a-1217-2397Rudrapal M Khairnar SJ Borse LB Jadhav AG Coronavirus Disease-2019 (COVID-19): an updated review Drug Res (Stuttg) 2020 Sep709389 400 https://doi.org/10.1055/a-1217-239710.1055/a-1217-2397751636932746481Search in Google Scholar

Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987 Jul;4(4): 406–425. https://doi.org/10.1093/oxfordjournals.molbev.a040454Saitou N Nei M The neighbor-joining method: a new method for reconstructing phylogenetic trees Mol Biol Evol 1987 Jul44 406 425 https://doi.org/10.1093/oxfordjournals.molbev.a04045410.1093/oxfordjournals.molbev.a0404543447015Search in Google Scholar

Saxena SK, Kumar S, Ansari S, Paweska JT, Maurya VK, Tripathi AK, Abdel-Moneim AS. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective. J Med Virol. 2022 Apr;94(4):1738–1744. https://doi.org/10.1002/jmv.27524Saxena SK Kumar S Ansari S Paweska JT Maurya VK Tripathi AK Abdel-Moneim AS Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective J Med Virol 2022 Apr9441738 1744 https://doi.org/10.1002/jmv.2752410.1002/jmv.2752434905235Search in Google Scholar

Sharma V, Rai H, Gautam DNS, Prajapati PK, Sharma R. Emerging evidence on Omicron (B.1.1.529) SARS-CoV-2 variant. J Med Virol. 2022 May;94(5):1876–1885. https://doi.org/10.1002/jmv.27626Sharma V Rai H Gautam DNS Prajapati PK Sharma R Emerging evidence on Omicron (B.1.1.529) SARS-CoV-2 variant J Med Virol 2022 May9451876 1885 https://doi.org/10.1002/jmv.2762610.1002/jmv.27626901559635083761Search in Google Scholar

Shishir TA, Naser IB, Faruque SM. In silico comparative genomics of SARS-CoV-2 to determine the source and diversity of the pathogen in Bangladesh. PLoS One. 2021 Jan;16(1):e0245584. https://doi.org/10.1371/journal.pone.0245584Shishir TA Naser IB Faruque SM In silico comparative genomics of SARS-CoV-2 to determine the source and diversity of the pathogen in Bangladesh PLoS One 2021 Jan161e0245584 https://doi.org/10.1371/journal.pone.024558410.1371/journal.pone.0245584781702233471859Search in Google Scholar

Sofi MS, Hamid A, Bhat SU. SARS-CoV-2: A critical review of its history, pathogenesis, transmission, diagnosis and treatment. Biosaf Health. 2020 Dec;2(4):217–225. https://doi.org/10.1016/j.bsheal.2020.11.002Sofi MS Hamid A Bhat SU SARS-CoV-2: A critical review of its history, pathogenesis, transmission, diagnosis and treatment Biosaf Health 2020 Dec24217 225 https://doi.org/10.1016/j.bsheal.2020.11.00210.1016/j.bsheal.2020.11.002764888833196035Search in Google Scholar

Tamura K, Nei M, Kumar S. Prospects for inferring very large phylogenies by using the neighbor-joining method. Proc Natl Acad Sci USA. 2004 Jul;101(30):11030–11035. https://doi.org/10.1073/pnas.0404206101Tamura K Nei M Kumar S Prospects for inferring very large phylogenies by using the neighbor-joining method Proc Natl Acad Sci USA 2004 Jul1013011030 11035 https://doi.org/10.1073/pnas.040420610110.1073/pnas.040420610149198915258291Search in Google Scholar

Tan Z, Chen Z, Yu A, Li X, Feng Y, Zhao X, Xu W, Su X. The first two imported cases of SARS-CoV-2 Omicron variant – Tianjin Municipality, China, December 13, 2021. China CDC Wkly. 2022 Jan; 4(4):76–77. https://doi.org/10.46234/ccdcw2021.266Tan Z Chen Z Yu A Li X Feng Y Zhao X Xu W Su X The first two imported cases of SARS-CoV-2 Omicron variant – Tianjin Municipality, China, December 13, 2021 China CDC Wkly 2022 Jan 4476 77 https://doi.org/10.46234/ccdcw2021.26610.46234/ccdcw2021.266883744335186373Search in Google Scholar

Thakur V, Ratho RK. OMICRON (B.1.1.529): A new SARS-CoV-2 variant of concern mounting worldwide fear. J Med Virol. 2022 May; 94(5):1821–1824. https://doi.org/10.1002/jmv.27541Thakur V Ratho RK OMICRON (B.1.1.529): A new SARS-CoV-2 variant of concern mounting worldwide fear J Med Virol 2022 May 9451821 1824 https://doi.org/10.1002/jmv.2754110.1002/jmv.2754134936120Search in Google Scholar

Vardhan S, Sahoo SK. Computational studies on the interaction of SARS-CoV-2 Omicron SGp RBD with human receptor ACE2, limonin and glycyrrhizic acid. Comput Biol Med. 2022a May; 144: 105367. https://doi.org/10.1016/j.compbiomed.2022.105367Vardhan S Sahoo SK Computational studies on the interaction of SARS-CoV-2 Omicron SGp RBD with human receptor ACE2, limonin and glycyrrhizic acid Comput Biol Med 2022a May 144 105367 https://doi.org/10.1016/j.compbiomed.2022.10536710.1016/j.compbiomed.2022.105367888668735247766Search in Google Scholar

Vardhan S, Sahoo SK. Exploring the therapeutic nature of limonoids and triterpenoids against SARS-CoV-2 by targeting nsp13, nsp14, and nsp15 through molecular docking and dynamics simulations. J Tradit Complement Med. 2022b Jan;12(1):44–54. https://doi.org/10.1016/j.jtcme.2021.12.002Vardhan S Sahoo SK Exploring the therapeutic nature of limonoids and triterpenoids against SARS-CoV-2 by targeting nsp13, nsp14, and nsp15 through molecular docking and dynamics simulations J Tradit Complement Med 2022b Jan12144 54 https://doi.org/10.1016/j.jtcme.2021.12.00210.1016/j.jtcme.2021.12.002866629334926189Search in Google Scholar

Wang L, Cheng G. Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa. J Med Virol. 2022 Apr; 94(4): 1728–1733. https://doi.org/10.1002/jmv.27516Wang L Cheng G Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa J Med Virol 2022 Apr 944 1728 1733 https://doi.org/10.1002/jmv.2751610.1002/jmv.2751634897752Search in Google Scholar

Wang R, Chen J, Wei GW. Mechanisms of SARS-CoV-2 evolution revealing vaccine-resistant mutations in Europe and America. J Phys Chem Lett. 2021 Dec;12(49):11850–11857. https://doi.org/10.1021/acs.jpclett.1c03380Wang R Chen J Wei GW Mechanisms of SARS-CoV-2 evolution revealing vaccine-resistant mutations in Europe and America J Phys Chem Lett 2021 Dec124911850 11857 https://doi.org/10.1021/acs.jpclett.1c0338010.1021/acs.jpclett.1c03380867243534873910Search in Google Scholar

Yi C, Sun X, Ye J, Ding L, Liu M, Yang Z, Lu X, Zhang Y, Ma L, Gu W, et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell Mol Immunol. 2020 Jun;17(6):621–630. https://doi.org/10.1038/s41423-020-0458-zYi C Sun X Ye J Ding L Liu M Yang Z Lu X Zhang Y Ma L Gu W et al Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies Cell Mol Immunol 2020 Jun176621 630 https://doi.org/10.1038/s41423-020-0458-z10.1038/s41423-020-0458-z722745132415260Search in Google Scholar

Zhang X, Wu S, Wu B, Yang Q, Chen A, Li Y, Zhang Y, Pan T, Zhang H, He X. SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance. Signal Transduct Target Ther. 2021 Dec;6(1):430. https://doi.org/10.1038/s41392-021-00852-5Zhang X Wu S Wu B Yang Q Chen A Li Y Zhang Y Pan T Zhang H He X SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance Signal Transduct Target Ther 2021 Dec61430 https://doi.org/10.1038/s41392-021-00852-510.1038/s41392-021-00852-5867897134921135Search in Google Scholar

Articles recommandés par Trend MD

Planifiez votre conférence à distance avec Sciendo